Annals of Surgical Oncology

, Volume 14, Issue 5, pp 1551–1559 | Cite as

Restaging of Differentiated Thyroid Carcinoma by the Sixth Edition AJCC/UICC TNM Staging System: Stage Migration and Predictability

  • Brian Lang
  • Chung-Yau Lo
  • Wai-Fan Chan
  • King-Yin Lam
  • Koon-Yat Wan
Endocrine Tumors

Abstract

Background

The AJCC/UICC TNM staging system (TNM) is a widely accepted system for differentiated thyroid carcinoma (DTC). The objective of the present study was to evaluate the potential changes in cancer-specific survival (CSS) after reclassification from fifth to sixth edition TNM.

Methods

A total of 760 DTC patients managed at our institution from 1961 to 2001 were retrospectively restaged from the fifth to sixth edition TNM. CSS were calculated using Kaplan–Meier method and were compared by the log-rank test. The relative ability of each edition in predicting CSS was calculated by the proportion of variance explained (PVE).

Results

Upon reclassification, the proportion of T1 and T3 tumors increased from 14.2 to 33.4% and 10.0 to 33.7%; T2 and T4 decreased from 44.2 to 25.0% and 31.6 to 7.9%, respectively; N0 remained unchanged at 66.0%; N1a decreased from 25.7 to 4.7%; N1b increased from 8.4 to 29.3%; stages I and IV tumors increased from 55.7 to 60.3% and 3.4 to 17.6%, respectively; stages II and III tumors decreased from 20.5 to 13.9% and 20.4 to 8.2%, respectively. The sixth edition had a higher PVE value than the fifth edition. Significant differences in CSS were observed between stage III (fifth edition) and stage III (sixth edition) and between stage IV (fifth edition) and stage IVA (sixth edition).

Conclusions

The sixth edition TNM caused marked changes in the pT, pN and allocation of patients into different tumor stages. It appeared to have superior predictability over the fifth edition.

Keywords

TNM Differentiated thyroid carcinoma Papillary thyroid carcinoma Follicular thyroid carcinoma Staging Risk stratification 

References

  1. 1.
    Patel SG, Shah JP. TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J Clin 2005; 55:242–58PubMedGoogle Scholar
  2. 2.
    Byar DP, Green SB, Dor P, Williams ED, Colon J, van Gilse HA, Mayer M, Sylvester RJ, van Glabbeke M. A prognostic index for thyroid carcinoma: a study of the EORTC Thyroid Cancer Cooperative Group. Eur J Cancer 1979; 15:1033–41PubMedGoogle Scholar
  3. 3.
    Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988; 104(6):947–53PubMedGoogle Scholar
  4. 4.
    Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. Cancer 1998; 83:1012–21PubMedCrossRefGoogle Scholar
  5. 5.
    Gospodarowicz MK, Miller D, Groome PA, Greene FL, Logan PA, Sobin LH. The process for continuous improvement of the TNM classification. Cancer 2004; 100:1–5PubMedCrossRefGoogle Scholar
  6. 6.
    Comparison Guide. AJCC cancer staging manual, fifth vs sixth edition. Available: http://www.cancerstaging.org/products/ajccproducts.html [accessed 11th February 2005]
  7. 7.
    Pellegriti G, Scollo C, Lumera G, Regalbuto C, Vigneri R, Belfiore A. Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases. J Clin Endocrinol Metab 2004; 89:3713–20PubMedCrossRefGoogle Scholar
  8. 8.
    Dobert N, Menzel C, Oeschger S, Grünwald. Differentiated thyroid carcinoma: the new UICC sixth edition TNM classification system in a retrospective analysis of 169 patients. Thyroid 2004; 14(1):65–70PubMedCrossRefGoogle Scholar
  9. 9.
    Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, et al. Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival. World J Surg 2006; 30:1–7CrossRefGoogle Scholar
  10. 10.
    Sherman SI. Toward a standard clinicopathologic staging approach for differentiated thyroid carcinoma. Semin Surg Oncol 1999; 16:12–5PubMedCrossRefGoogle Scholar
  11. 11.
    Shaha AR. Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer. Laryngoscope 2004; 114:393–402PubMedCrossRefGoogle Scholar
  12. 12.
    Sobin LH, Wittekind Ch. (1997) UICC TNM classification of malignant tumours, 5th edn. New York: Wiley-LissGoogle Scholar
  13. 13.
    Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M. (2002) AJCC cancer staging handbook: TNM classification of malignant tumors, 6th edn. New York: Springer-VerlagGoogle Scholar
  14. 14.
    Wittekind Ch, Greene FL, Henson DE, Hutter RVP, Sobin LH. (2003) TNM supplement: a commentary on uniform use, 3rd edn. New York: Wiley-LissGoogle Scholar
  15. 15.
    DeLellis RA, Lloyd RV, Heitz PU, Eng C. World Health Organization classification of tumours: pathology and genetics of tumours of endocrine organs. France: IARC (International Agency for Research on Cancer) Press; 2004Google Scholar
  16. 16.
    Schemper M, Stare J. Explained variation in survival analysis. Stat Med 1996; 15:1999–2012PubMedCrossRefGoogle Scholar
  17. 17.
    Greene FL. TNM: Our language of cancer. CA Cancer J Clin 2004; 54:129–30PubMedCrossRefGoogle Scholar
  18. 18.
    Brierley JD, Panzarella T, Tsang RW, Gospodarowicz MK, O’Sullivan B. A comparison of different staging systems. Predictability of patient outcome. Thyroid carcinoma as an example. Cancer 1997; 79:2414–23PubMedCrossRefGoogle Scholar
  19. 19.
    Passler C, Prager G, Scheuba C, Kaserer K, Zettinig G, Niederle B. Application of staging systems for differentiated thyroid carcinoma in an endemic goiter region with iodine substitution. Ann Surg 2003; 207(2):227–34CrossRefGoogle Scholar
  20. 20.
    Yildirim E. A model for predicting outcomes in patients with differentiated thyroid cancer and model performance in comparison with other classification systems. J Am Coll Surg 2005; 200:378–92PubMedCrossRefGoogle Scholar
  21. 21.
    DeGroot LJ, Kaplan EL, McCormick M, et al. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metabol 1990:71:414–24CrossRefGoogle Scholar
  22. 22.
    Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993; 114(6):1050–8PubMedGoogle Scholar
  23. 23.
    Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97:418–28PubMedCrossRefGoogle Scholar
  24. 24.
    Goropoulos A, Karamoshos K, Christodoulou A, Ntitsias T, Paulou K, Samaras A, Xirou P, Efstratiou I. Value of the cervical compartments in the surgical treatment of papillary thyroid carcinoma. World J Surg 2004; 28(12):1275–81PubMedCrossRefGoogle Scholar
  25. 25.
    Pereira JA, Jimeno J, Miquel J, Igesias M, Munne A, Sancho JJ, Sitges-Serra A. Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma. Surgery 2005; 138(6):1095–101PubMedCrossRefGoogle Scholar
  26. 26.
    Sobin LH. TNM: principles, history, and relation to other prognostic factors. Cancer 2001; 91(8):1589–92PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2007

Authors and Affiliations

  • Brian Lang
    • 1
  • Chung-Yau Lo
    • 1
  • Wai-Fan Chan
    • 1
  • King-Yin Lam
    • 2
  • Koon-Yat Wan
    • 3
  1. 1.Division of Endocrine Surgery, Department of SurgeryUniversity of Hong Kong Medical Centre, Queen Mary HospitalHong Kong SARChina
  2. 2.Discipline of Pathology, School of MedicineGriffith UniversityGold CoastAustralia
  3. 3.Department of Clinical OncologyUniversity of Hong Kong Medical Centre, Queen Mary HospitalHong Kong SARChina

Personalised recommendations